ASX Announcements


 
11-Jan-2021    European Commission grants 3 NNZ-2591 Orphan designations  
 
7-Dec-2020    Notification of investor briefing webinar  
 
7-Dec-2020    Neuren receives notice of positive opinion on all three Orphan designation applications for NNZ-2591  
 
19-Nov-2020    Approval received for final stage of NNZ-2591 clinical trial  
 
29-Oct-2020    Quarterly report and cash flow statement for Q3 2020  
 
29-Sep-2020    Neuren requests Orphan designations for NNZ-2591 in Europe  
 
22-Sep-2020    Neuren initiates manufacture of NNZ-2591 for Phase 2 trials  
 
26-Aug-2020    Half-year Shareholder Update  
 
26-Aug-2020    Half Yearly Report and Accounts  
 
18-Aug-2020    Corporate presentation, 18 August 2020  
 
11-Aug-2020    Change of Director's Interest Notice  
 
7-Aug-2020    Appendix 2A  
 
7-Aug-2020    Change of Director's Interest Notice  
 
5-Aug-2020    Completion of Share Purchase Plan  
 
30-Jul-2020    Appointment of CFO & Company Secretary  
 
27-Jul-2020    Q2 2020 Activity Report and Cash Flow Report  
 
14-Jul-2020    Final share buy-back notice - Appendix 3F  
 
14-Jul-2020    Announcement of buy-back - Appendix 3C  
 
14-Jul-2020    Scientific publications and presentations for trofinetide and NNZ-2591  
 
13-Jul-2020    Appendix 3G  
 
9-Jul-2020    Share Purchase Plan Offer Booklet  
 
6-Jul-2020    Section 708A notice  
 
6-Jul-2020    Appendix 2A  
 
1-Jul-2020    Electing to receive SPP documents by e-mail  
 
29-Jun-2020    Results of Meeting  
 
29-Jun-2020    AGM Chairman's Address and CEO Presentation  
 
29-Jun-2020    Proposed issue of Securities - NEU  
 
29-Jun-2020    Neuren successfully completes $20m capital raising  
 
25-Jun-2020    Trading Halt  
 
16-Jun-2020    Temporary enrolment pause ended in Phase 3 trial in the US  
 
2-Jun-2020    Change of Director's Interest Notice  
 
1-Jun-2020    Change of Director's Interest Notice  
 
29-May-2020    Final Director's Interest Notice  
 
28-May-2020    Virtual AGM online guide  
 
28-May-2020    Notice of Annual General Meeting/Proxy Form  
 
27-May-2020    Neuren announces changes to leadership team  
 
7-May-2020    Neuren commences first clinical trial for NNZ-2591  
 
29-Apr-2020    Appendix 4G  
 
29-Apr-2020    Annual Report 2019  
 
17-Apr-2020    Appendix 4C - quarterly  
 
17-Apr-2020    Q1 2020 Activity Report  
 
6-Apr-2020    Corporate presentation, 6 April 2020  
 
2-Apr-2020    First patent in Israel granted for trofinetide  
 
26-Mar-2020    Change of Director's Interest Notice  
 
26-Mar-2020    New international institutional shareholder acquires 14% of Neuren  
 
24-Mar-2020    Change of Director's Interest Notice  
 
24-Mar-2020    Temporary pause in new enrolments for LAVENDER trial in US  
 
20-Mar-2020    Trading Halt  
 
17-Mar-2020    Neuren to capture substantially greater value after Phase 3  
 
10-Mar-2020    Additional information  
 
6-Mar-2020    Compelling results for NNZ-2591 dose ranging study in Phelan-McDermid syndrome model  
 
4-Mar-2020    Commentary on potential benefit to Neuren of RPD designation  
 
4-Mar-2020    Rare Pediatric Disease designation received from FDA  
 
26-Feb-2020    5 Orphan Drug programs and Rett in Phase 3 funded by partner  
 
26-Feb-2020    Appendix 4E and 2019 full year accounts  
 
19-Feb-2020    Update on trofinetide Phase 3 trial in Rett syndrome  
 
28-Jan-2020    Appendix 4C - quarterly  
 
12-Dec-2019    2019 year-end update and 2020 outlook  
 
3-Dec-2019    Patent to 2034 granted in Europe for Neuren's NNZ-2591  
 
31-Oct-2019    Phase 3 trial of trofinetide in Rett syndrome commences  
 
18-Oct-2019    Neuren Corporate Presentation, October 2019  
 
17-Oct-2019    Appendix 4C - quarterly  
 
16-Oct-2019    FDA grants Orphan Drug designation for NNZ-2591 in Phelan-McDermid and Pitt Hopkins syndromes  
 
16-Oct-2019    Pause in Trading  
 
11-Oct-2019    FDA grants Orphan Drug Designation for NNZ-2591 in Angelman  
 
20-Sep-2019    Neuren approaching key milestones in Q4 2019  
 
28-Aug-2019    Neuren advances pipeline for neurodevelopmental disorders  
 
28-Aug-2019    Half Yearly Report and Accounts  
 
16-Aug-2019    New patent granted for Neuren's NNZ-2591 in Japan  
 
31-Jul-2019    Appendix 4C - quarterly  
 
29-Jul-2019    Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA  
 
16-Jul-2019    Neuren receives final payment from Lanstead Capital  
 
28-May-2019    Results of Meeting  
 
28-May-2019    Chairman's Address at 2019 Annual Meeting of Shareholders  
 
17-May-2019    Validation for NNZ-2591 neurodevelopmental disorder pipeline  
 
17-May-2019    NNZ-2591 positive effects in Pitt Hopkins syndrome model  
 
17-May-2019    NNZ-2591 positive effects in Angelman syndrome model  
 
30-Apr-2019    Appendix 4C - quarterly  
 
29-Apr-2019    Notice of Annual General Meeting/Proxy Form  
 
26-Apr-2019    Appendix 4G  
 
26-Apr-2019    Annual Report to shareholders  
 
26-Apr-2019    Update on development plan for NNZ-2591  
 
28-Mar-2019    Neuren's Rett syndrome Phase 2 trial published in Neurology  
 
27-Feb-2019    Fundamentals strong as Neuren advances neuroscience pipeline  
 
27-Feb-2019    Preliminary Final Report and statutory accounts  
 
18-Feb-2019    NNZ-2591 positive effects in Phelan-McDermid syndrome model  
 
4-Feb-2019    Plans for Phase 3 trial in Rett syndrome  
 
1-Feb-2019    Neuren retains ex-North America, appoints investment bank  
 
31-Jan-2019    Appendix 4C - quarterly  
 
3-Jan-2019    Final Director's Interest Notice  
 
31-Dec-2018    Ceasing to be a substantial holder  
 
18-Dec-2018    2018 Year-end Business Update  
 
17-Dec-2018    Larry Glass to retire as a director and continue as CSO  
 
2-Nov-2018    Presentation at AusBiotech Invest and Partnering 2018  
 
31-Oct-2018    Appendix 4C - quarterly  
 
26-Oct-2018    Trofinetide ex-North America exclusive negotiation period  
 
17-Oct-2018    Neuren and ACADIA hold Rett syndrome SAB meeting  
 
1-Oct-2018    Change of Director's Interest Notice  
 
21-Sep-2018    FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID  
 
6-Sep-2018    Investor presentation, 6 September 2018  
 
31-Aug-2018    Half Yearly Report and Accounts  
 
29-Aug-2018    Neuren and Lanstead agree to pause settlements for 120 days  
 
22-Aug-2018    Appointment of auditor  
 
22-Aug-2018    Neuren receives initial payment of US$10 million from ACADIA  
 
16-Aug-2018    Change of Director's Interest Notice  
 
15-Aug-2018    Change of Director's Interest Notice  
 
7-Aug-2018    Investor update  
 
7-Aug-2018    Neuren and ACADIA announce agreement for North America  
 
31-Jul-2018    Appendix 4C - quarterly  
 
9-Jul-2018    Initial Director's Interest Notice  
 
5-Jul-2018    Initial Director's Interest Notice  
 
5-Jul-2018    Initial Director's Interest Notice  
 
4-Jul-2018    Neuren announces new appointments to the board of directors  
 
18-Jun-2018    Results of Meeting  
 
18-Jun-2018    Chairman's Address at 2018 Annual Shareholders' Meeting  
 
30-May-2018    Change of Director's Interest Notice  
 
30-May-2018    Final share buy-back notice - Appendix 3F  
 
30-May-2018    Announcement of buy-back - Appendix 3C  
 
23-May-2018    Notice under section 708A(5)(e) of the Corporations Act  
 
23-May-2018    Appendix 3B  
 
21-May-2018    Neuren announces investment and exclusive negotiation period  
 
14-May-2018    Notice of Annual General Meeting/Proxy Form  
 
8-May-2018    Appendix 4G  
 
8-May-2018    Annual Report to shareholders  
 
30-Apr-2018    Appendix 4C - quarterly  
 
30-Apr-2018    First patent in Japan granted for Neuren's trofinetide  
 
29-Mar-2018    Full Year Statutory Accounts  
 
29-Mar-2018    Disclosure under Listing Rule 4.3D  
 
9-Mar-2018    S&P DJ Indices Announces March Quarterly Rebalance  
 
28-Feb-2018    Preliminary Final Report  
 
30-Jan-2018    Appendix 4C - quarterly  
 
29-Dec-2017    Final Director's Interest Notice  
 
29-Dec-2017    Non-executive director retirement  
 
27-Dec-2017    Change in substantial holding  
 
5-Dec-2017    Neuren announces new US patent to be granted for NNZ-2591  
 
16-Nov-2017    Consolidation/Split - NEU  
 
16-Nov-2017    Notification under Listing Rule 7.20 of share reorganisation  
 
26-Oct-2017    Appendix 4C - quarterly  
 
13-Oct-2017    Neuren FDA meeting confirms Phase 3 plan for Rett syndrome  
 
6-Oct-2017    Investor presentation, 6 October 2017  
 
5-Oct-2017    Presentations and publication for Rett syndrome trials  
 
30-Aug-2017    Change of Director's Interest Notice  
 
30-Aug-2017    Change of Director's Interest Notice  
 
30-Aug-2017    Change of Director's Interest Notice  
 
29-Aug-2017    Notice under section 708A(5)(e) of the Corporations Act  
 
29-Aug-2017    Appendix 3B  
 
29-Aug-2017    Results of Meeting  
 
24-Aug-2017    Neuren reports 2017 half-year results  
 
24-Aug-2017    Half Yearly Report and Accounts  
 
14-Aug-2017    Notice of special meeting of shareholders  
 
27-Jul-2017    Appendix 4C - quarterly  
 
21-Jul-2017    Becoming a substantial holder  
 
20-Jul-2017    Neuren granted Type B Meeting with FDA for Rett syndrome  
 
19-Jul-2017    Notice under section 708A(5)(e) of the Corporations Act  
 
19-Jul-2017    Appendix 3B  
 
13-Jul-2017    Notice under section 708A(5)(e) of the Corporations Act  
 
13-Jul-2017    Appendix 3B  
 
29-Jun-2017    Results of Meeting  
 
29-Jun-2017    2017 AGM Chairman's Address  
 
29-Jun-2017    Neuren secures funding for key activities for Rett syndrome  
 
28-Jun-2017    Response to ASX Price Query  
 
27-Jun-2017    Trading Halt  
 
2-Jun-2017    Investor presentation, 2 June 2017  
 
31-May-2017    Neuren announces grant of two new patents to 2032  
 
29-May-2017    Notice of Annual General Meeting/Proxy Form  
 
8-May-2017    Response to Appendix 4C Query  
 
28-Apr-2017    Appendix 4C - quarterly  
 
28-Apr-2017    Appendix 4G  
 
28-Apr-2017    Annual Report to shareholders  
 
4-Apr-2017    Neuren receives $1 million R&D Tax Incentive  
 
3-Apr-2017    Investor presentation, 3 April 2017  
 
30-Mar-2017    Full Year Statutory Accounts  
 
22-Mar-2017    Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome  
 
17-Mar-2017    Trading Halt  
 
10-Mar-2017    S&P DJ Indices Announces March Quarterly Rebalance  
 
23-Feb-2017    Preliminary Final Report  
 
2-Feb-2017    Investor presentation, 2 February 2017  
 
31-Jan-2017    Appendix 4C - quarterly  
 
30-Jan-2017    Neuren completes Phase 2 trial in pediatric Rett syndrome  
 
6-Dec-2016    Results of Meeting  
 
25-Nov-2016    Investor presentation, 25 November 2016  
 
14-Nov-2016    Notice of special meeting of shareholders  
 
14-Nov-2016    Neuren completes enrolment in Rett syndrome Phase 2 trial  
 
31-Oct-2016    Appendix 4C - quarterly  
 
28-Oct-2016    Neuren receives $0.9m from exercise of last expiring options  
 
28-Oct-2016    Appendix 3B  
 
9-Sep-2016    Change of Melbourne Registry Address Notification  
 
31-Aug-2016    Change of Director's Interest Notice  
 
31-Aug-2016    Appendix 3B  
 
30-Aug-2016    Half Yearly Report and Accounts  
 
25-Aug-2016    Neuren expands Phase 2 Rett syndrome pediatric trial  
 
26-Jul-2016    Appendix 4C - quarterly  
 
24-Jun-2016    Neuren presents at Rettsyndrome.org 2016 Research Symposium  
 
22-Jun-2016    Grant of new patent for Autism Spectrum Disorders  
 
31-May-2016    Results of Meeting  
 
31-May-2016    Chairman's Address to Shareholders  
 
16-May-2016    Change of Director's Interest Notice  
 
13-May-2016    Presentation at 6th Annual TBI Conference, Washington DC  
 
2-May-2016    Notice of Annual General Meeting/Proxy Form  
 
29-Apr-2016    Appendix 4C - quarterly  
 
26-Apr-2016    Neuren Shareholder Update  
 
26-Apr-2016    Results of Phase 2 trial in moderate to severe TBI  
 
22-Apr-2016    Trading Halt  
 
18-Apr-2016    Appendix 4G  
 
18-Apr-2016    Annual Report to shareholders  
 
7-Apr-2016    First subject commences Neuren's Rett syndrome Phase 2 trial  
 
25-Feb-2016    Neuren reports 2015 full-year financial results  
 
25-Feb-2016    Appendix 4E and Financial Report 31 December 2015  
 
29-Jan-2016    Appendix 4C - quarterly  
 
11-Jan-2016    Neuren Investor Presentation, 11 January 2016  
 
4-Jan-2016    Neuren Shareholder Update, January 2016  
 
30-Dec-2015    Appendix 3B  
 
7-Dec-2015    Trofinetide successful in Phase 2 trial in Fragile X  
 
3-Dec-2015    Trading Halt  
 
30-Nov-2015    Grant of composition patent in Europe for Neuren's NNZ-2591  
 
17-Nov-2015    Corporations Act Notice  
 
17-Nov-2015    Appendix 3B  
 
9-Nov-2015    Shareholders provide further support for Rett syndrome  
 
29-Oct-2015    Neuren completes enrolment in INTREPID clinical trial  
 
21-Oct-2015    Appendix 4C - quarterly  
 
13-Oct-2015    IRSF confirms financial support for Neuren's clinical trials  
 
12-Oct-2015    New US patent covering use of trofinetide for Rett syndrome  
 
29-Sep-2015    Neuren provides update on Fragile X and INTREPID trials  
 
25-Aug-2015    Half Yearly Report and Accounts 30 June 2015  
 
14-Aug-2015    trofinetide confirmed as INN for Neuren's NNZ-2566  
 
13-Aug-2015    Neuren confirms orphan drug designations in Europe  
 
31-Jul-2015    Investor presentation, 31 July 2015  
 
30-Jul-2015    Appendix 4C - quarterly  
 
29-Jul-2015    Neuren reports progress in orphan drug programs  
 
1-Jun-2015    Appendix 3B  
 
7-May-2015    Appendix 3B  
 
28-Apr-2015    Results of Meeting  
 
28-Apr-2015    Chairman's Address to Shareholders  
 
22-Apr-2015    Appendix 3B  
 
21-Apr-2015    Appendix 4C - quarterly  
 
26-Mar-2015    Appendix 3B  
 
25-Mar-2015    Notice of Annual General Meeting/Proxy Form  
 
25-Mar-2015    Annual Report to shareholders  
 
2-Mar-2015    Neuren receives response to request for Breakthrough Therapy  
 
25-Feb-2015    Neuren reports 2014 full-year financial results  
 
25-Feb-2015    Preliminary Final Report and 2014 full year accounts  
 
16-Feb-2015    FDA grants Neuren Orphan Drug designation for Rett syndrome  
 
6-Feb-2015    Appendix 3B  
 
5-Feb-2015    Change of Director's Interest Notice  
 
29-Jan-2015    Updated Share Trading Policy  
 
28-Jan-2015    Neuren announces trofinetide as proposed INN for NNZ-2566  
 
27-Jan-2015    Appendix 3B  
 
22-Jan-2015    Appendix 4C - quarterly  
 
8-Jan-2015    Investor Presentation, 8 January 2015  
 
5-Jan-2015    Response to ASX Price Query  
 
30-Dec-2014    Neuren submits Orphan Drug/Breakthrough Therapy applications  
 
23-Dec-2014    Appendix 3B  
 
3-Dec-2014    Appendix 3B  
 
27-Nov-2014    Investor presentation, 27 November 2014  
 
20-Nov-2014    Appendix 3B  
 
12-Nov-2014    Neuren successful in Rett syndrome Phase 2 trial  
 
10-Nov-2014    Trading Halt  
 
28-Oct-2014    Appendix 3B  
 
17-Oct-2014    Appendix 4C - quarterly  
 
9-Oct-2014    Change of Director's Interest Notice  
 
9-Oct-2014    Appendix 3B  
 
24-Sep-2014    Appendix 3B  
 
24-Sep-2014    Issue of long term incentives  
 
24-Sep-2014    Neuren to release Rett Syndrome trial results in November  
 
8-Sep-2014    Enrolment commences in Neuren's Concussion Phase 2 trial  
 
4-Sep-2014    Investor presentation, 4 September 2014  
 
29-Aug-2014    Appendix 3B  
 
28-Aug-2014    Neuren reports 2014 half-year financial results  
 
27-Aug-2014    Half Yearly Report and Accounts  
 
15-Aug-2014    Appendix 3B  
 
12-Aug-2014    Neuren advances NNZ-2591 towards IND application  
 
22-Jul-2014    Appendix 3B  
 
18-Jul-2014    Appendix 4C - quarterly  
 
17-Jul-2014    US$3m increase to US Army grant and INTREPID outlook update  
 
10-Jul-2014    Neuren receives ethics approval to start Concussion trial  
 
26-Jun-2014    Neuren completes enrolment in Phase 2 trial in Rett Syndrome  
 
25-Jun-2014    Appendix 3B  
 
23-Jun-2014    Neuren appoints CMC expert to leadership team  
 
4-Jun-2014    Neuren receives new US patent for NNZ-2591  
 
3-Jun-2014    Appendix 3B  
 
3-Jun-2014    Appendix 3B  
 
30-May-2014    Appendix 3B  
 
21-May-2014    Neuren presents at International Meeting for Autism Research  
 
14-May-2014    Appendix 3B  
 
30-Apr-2014    Appendix 3B  
 
30-Apr-2014    AGM Results of Meeting  
 
30-Apr-2014    Chairman's AGM Address to Shareholders  
 
30-Apr-2014    Appendix 4C - quarterly  
 
2-Apr-2014    Presentation at Morgans Emerging Companies Conference  
 
27-Mar-2014    Notice of Annual General Meeting - Proxy Form  
 
27-Mar-2014    Appendix 3B  
 
27-Mar-2014    2013 Annual Report  
 
7-Mar-2014    ZSP S and P DJ Indices Announces March Quarterly Rebalance  
 
27-Feb-2014    Neuren reports financial results for 2013  
 
27-Feb-2014    Preliminary Final Report and audited Financial Statements  
 
21-Feb-2014    Appendix 3B  
 
14-Feb-2014    Appendix 3B  
 
28-Jan-2014    Neuren reports progress in NNZ-2566 clinical trial programs  
 
15-Jan-2014    Appendix 3B  
 
2-Jan-2014    Appendix 3B  
 
29-Nov-2013    Appendix 3B  
 
27-Nov-2013    Appendix 3B  
 
27-Nov-2013    Neuren Share Purchase Plan raises $2 million  
 
20-Nov-2013    Ceasing to be a substantial holder  
 
19-Nov-2013    Investor presentation, 19 November 2013  
 
15-Nov-2013    Appendix 3B  
 
14-Nov-2013    Change in substantial holding  
 
12-Nov-2013    Appendix 3B  
 
6-Nov-2013    Change of Director's Interest Notice  
 
4-Nov-2013    Share Purchase Plan record date  
 
4-Nov-2013    SPP Certification  
 
4-Nov-2013    Appendix 3B  
 
31-Oct-2013    Becoming a substantial holder  
 
30-Oct-2013    Share Purchase Plan offer documents  
 
30-Oct-2013    Orphan drug designation from FDA for NNZ-2566 in Fragile X  
 
28-Oct-2013    Section 708A(5)e Notice  
 
28-Oct-2013    Appendix 3B  
 
22-Oct-2013    Placement of $21.5m to accelerate execution of strategy  
 
18-Oct-2013    Neuren receives Fast Track designation for Fragile X  
 
18-Oct-2013    Trading Halt  
 
10-Oct-2013    Appendix 3B  
 
9-Oct-2013    Response to ASX Price Query  
 
9-Oct-2013    Investor presentation  
 
1-Oct-2013    Neuren data presented at Fragile X Foundation meeting  
 
26-Sep-2013    Appendix 3B  
 
19-Sep-2013    Change of Director's Interest Notice  
 
11-Sep-2013    Appendix 3B  
 
9-Sep-2013    Neuren opens new IND for NNZ-2566 in Fragile X Syndrome  
 
4-Sep-2013    Final Director's Interest Notice  
 
2-Sep-2013    Neuren announces changes to its leadership team  
 
29-Aug-2013    Half Yearly Report and Accounts  
 
5-Aug-2013    Notice under section 708A(5)(e) of the Corporations Act  
 
5-Aug-2013    Response to social media commentary re Rett trial  
 
5-Aug-2013    Trading Halt Request  
 
5-Aug-2013    Trading Halt  
 
30-Jul-2013    Investor presentation July 2013  
 
30-Jul-2013    Appendix 3B Option Exercise  
 
29-Jul-2013    Results in Fragile X Model with NNZ 2591  
 
26-Jul-2013    Response to ASX Price Query  
 
12-Jul-2013    Neuren receives two new patents  
 
11-Jul-2013    Notice under section 708A(5)(e) of the Corporations Act  
 
11-Jul-2013    Appendix 3B Option Exercise amended  
 
11-Jul-2013    Appendix 3B Option Exercise  
 
26-Jun-2013    Notice under section 708A(5)(e) of the Corporations Act  
 
26-Jun-2013    Appendix 3B Option Exercise  
 
25-Jun-2013    Response to ASX Price Query Letter  
 
18-Jun-2013    Notice under section 708A(5)(e) of the Corporations Act  
 
12-Jun-2013    Appendix 3B Option Exercise  
 
5-Jun-2013    FDA Fast Track granted for NNZ2566 Rett program  
 
29-May-2013    Change of Director's Interest Notice  
 
29-May-2013    Appendix 3B Equity Performance Rights  
 
29-May-2013    Appendix 3B Loan Funded Shares  
 
29-May-2013    Notice under section 708A(5)(e) of the Corporations Act  
 
24-May-2013    CFO appointment  
 
22-May-2013    Final Director's Interest Notice  
 
22-May-2013    Final Director's Interest Notice  
 
22-May-2013    Appendix 3B Exercise of Options  
 
22-May-2013    Lapse of Unlisted Options  
 
22-May-2013    Change of Director's Interest Notice  
 
22-May-2013    Change of Director's Interest Notice  
 
21-May-2013    Investor Presentation May 2013  
 
20-May-2013    Results of Meeting  
 
20-May-2013    CEO Presentation to AGM  
 
20-May-2013    Chairman's Address to AGM  
 
15-May-2013    Response to ASX Price Query Letter  
 
19-Apr-2013    Notice of Annual General Meeting/Proxy Form  
 
15-Apr-2013    Shareholder Update  
 
4-Apr-2013    Ceasing to be a substantial holder  
 
28-Mar-2013    Annual Report to shareholders  
 
28-Feb-2013    Preliminary Final Report  
 
1-Feb-2013    Initial Director's Interest Notice  
 
31-Jan-2013    Dr Richard Treagus joins Neuren Board  
 
9-Jan-2013    Neuren appoints Nancy Jones SD Clinical & Medical Affairs  
 
24-Dec-2012    Neuren IND open for Rett Phase II trial  
 
20-Dec-2012    Appendix 3B  
 
30-Nov-2012    Neuren TAP Conference presentation and Fragile X results  
 
22-Nov-2012    Neuren completes Phase I NNZ2566 study/files Phase II IND  
 
9-Nov-2012    Amended 2 - Change in substantial holding  
 
9-Nov-2012    Amended Change in substantial holding  
 
9-Nov-2012    Change in substantial holding  
 
25-Oct-2012    Response to ASX Price Query  
 
19-Oct-2012    NNZ2566 selected as Windhover Top 10 Neuroscience Project  
 
30-Aug-2012    Half Yearly Report and Accounts  
 
9-Aug-2012    Neuren appoints Joe Horrigan VP Clinical and Medical Affairs  
 
7-Aug-2012    NNZ2566 Rationale in ASDs  
 
6-Jul-2012    Neuren awarded Rett Syndrome trial grant  
 
8-Jun-2012    Final Director`s Interest Notice  
 
8-Jun-2012    Initial Director`s Interest Notice  
 
31-May-2012    Results of Meeting  
 
31-May-2012    CEO`s address to AGM  
 
29-May-2012    Neuren announces cancer xenograft testing results  
 
25-May-2012    Change in substantial holding  
 
16-May-2012    Rett Syndrome pre-IND meeting held with FDA  
 
2-May-2012    Notice under section 708A(5)(e) of the Corporations Act  
 
27-Apr-2012    Appendix 3B (exercise of options)  
 
27-Apr-2012    Notice of Annual General Meeting/Proxy Form  
 
19-Apr-2012    Response to ASX Price Query  
 
30-Mar-2012    Neuren 2011 Annual Report  
 
8-Mar-2012    Initial Director`s Interest Notice  
 
8-Mar-2012    Neuren appoints Bruce Hancox to board of directors  
 
8-Mar-2012    Neuren presentation to Arrowhead TBI Conference  
 
29-Feb-2012    Neuren 2011 Preliminary Final Report  
 
22-Dec-2011    Neuren to proceed with oral NNZ2566 trial  
 
12-Dec-2011    Change in substantial holding  
 
9-Dec-2011    Response to ASX Price Query  
 
21-Nov-2011    Neuren Completes Phase II trial Cohort 2  
 
7-Nov-2011    Appendix 3B (exercise of options)  
 
3-Nov-2011    Change in substantial holding  
 
3-Nov-2011    Change in substantial holding  
 
26-Oct-2011    Appendix 3B (amendment)  
 
26-Oct-2011    Change of Director`s Interest Notice  
 
26-Oct-2011    Change of Director`s Interest Notice  
 
26-Oct-2011    Change of Director`s Interest Notice  
 
26-Oct-2011    Change of Director`s Interest Notice  
 
26-Oct-2011    Change of Director`s Interest Notice  
 
26-Oct-2011    Appendix 3B  
 
20-Oct-2011    Response to ASX Price Query  
 
30-Aug-2011    Half Yearly Report and Accounts  
 
17-Aug-2011    Becoming a substantial holder  
 
16-Aug-2011    Becoming a substantial holder  
 
16-Aug-2011    Notice under section 708A(5)(e) of the Corporations Act  
 
16-Aug-2011    Appendix 3B  
 
16-Aug-2011    Neuren places $3m of rights issue shortfall  
 
29-Jul-2011    Appendix 4C - quarterly  
 
27-Jul-2011    NEU Broker Presentation July 2011  
 
22-Jul-2011    Neuren CEO presentation to Bioshares Biotech Summit  
 
21-Jul-2011    Change of Director`s Interest Notice  
 
21-Jul-2011    Change of Director`s Interest Notice  
 
19-Jul-2011    Appendix 3B  
 
19-Jul-2011    Results of Neuren Rights Issue  
 
29-Jun-2011    Neuren Confirms Despatch of Rights Issue Offer Documents  
 
28-Jun-2011    Appendix 3B  
 
24-Jun-2011    CEO presentation to AusBiotech New York  
 
20-Jun-2011    Rights Issue Eligible Shareholder Notice  
 
20-Jun-2011    Change in substantial holding  
 
15-Jun-2011    Rights Issue Notice to Foreign Shareholders  
 
15-Jun-2011    Rights Issue Notice to Optionholders  
 
15-Jun-2011    Rights Issue Notice under Section 708AA  
 
15-Jun-2011    Appendix 3B (renounceable rights issue)  
 
15-Jun-2011    Neuren Rights Issue Letter of Offer (Australian residents)  
 
15-Jun-2011    Neuren Rights Issue Offer Document (NZ residents)  
 
15-Jun-2011    Neuren announces Renounceable Rights Issue  
 
6-Jun-2011    Notice under section 708A(5)(e) of the Corporations Act  
 
6-Jun-2011    Neuren completes placement and converts remaining note  
 
6-Jun-2011    Appendix 3B (options)  
 
6-Jun-2011    Appendix 3B (shares)  
 
3-Jun-2011    Notice under section 708A(5)(e) of the Corporations Act  
 
3-Jun-2011    Appendix 3B  
 
2-Jun-2011    Notice under section 708A(5)(e) of the Corporations Act  
 
2-Jun-2011    Appendix 3B  
 
31-May-2011    Results of Annual Meeting  
 
31-May-2011    Results of Special Meeting  
 
31-May-2011    Neuren CEO Presentation to AGM  
 
20-May-2011    Neuren reduces outstanding convertible note principal  
 
19-May-2011    Neuren`s Perseis selects lead antibodies  
 
13-May-2011    Notice of Special Shareholders Meeting/Proxy Form  
 
11-May-2011    Neuren Completes Phase II trial Cohort 1  
 
6-May-2011    Notice under section 708A(5)(e) of the Corporations Act  
 
6-May-2011    Appendix 3B  
 
5-May-2011    Becoming a substantial holder  
 
4-May-2011    Neuren Announces Private Placement and Rights Issue  
 
2-May-2011    Trading Halt  
 
29-Apr-2011    Notice of Annual General Meeting/Proxy Form  
 
27-Apr-2011    Appendix 3B  
 
20-Apr-2011    Notice under section 708A(5)(e) of the Corporations Act  
 
20-Apr-2011    Appendix 3B  
 
20-Apr-2011    Appendix 3B  
 
31-Mar-2011    Annual Report to shareholders  
 
23-Mar-2011    Appendix 3B  
 
22-Mar-2011    Notice under section 708A(5)(e) of the Corporations Act  
 
21-Mar-2011    Appendix 3B  
 
21-Mar-2011    Appendix 3B  
 
21-Mar-2011    Appendix 3B  
 
21-Mar-2011    Results of Meeting  
 
10-Mar-2011    Response to ASX Price Query  
 
3-Mar-2011    Notice of Special Shareholders Meeting  
 
28-Feb-2011    Preliminary Final Report  
 
21-Feb-2011    Appendix 3B  
 
18-Feb-2011    Notice under section 708A(5)(e) of the Corporations Act  
 
18-Feb-2011    Appendix 3B  
 
8-Feb-2011    Lapse of unquoted options  
 
21-Jan-2011    Appendix 3B  
 
21-Jan-2011    Appendix 3B (amended)  
 
19-Jan-2011    Notice under section 708A(5)(e) of the Corporations Act  
 
19-Jan-2011    Appendix 3B  
 
19-Jan-2011    Appendix 3B  
 
22-Dec-2010    Appendix 3B  
 
20-Dec-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
20-Dec-2010    Securities Trading Policy  
 
20-Dec-2010    Appendix 3B  
 
20-Dec-2010    Appendix 3B  
 
22-Nov-2010    Appendix 3B  
 
19-Nov-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
19-Nov-2010    Appendix 3B  
 
19-Nov-2010    Appendix 3B  
 
18-Nov-2010    Neuren Initiates NNZ2566 Oral Formulation Development  
 
16-Nov-2010    Neuren Completes Additional Phase I Study for TBI  
 
27-Oct-2010    Appendix 3B  
 
20-Oct-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
20-Oct-2010    Appendix 3B  
 
20-Oct-2010    Appendix 3B  
 
7-Oct-2010    Lapse of unquoted options  
 
23-Sep-2010    Appendix 3B  
 
21-Sep-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
21-Sep-2010    Appendix 3B  
 
21-Sep-2010    Appendix 3B  
 
26-Aug-2010    Half Yearly Report and Accounts  
 
25-Aug-2010    Appendix 3B  
 
20-Aug-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
20-Aug-2010    Appendix 3B  
 
20-Aug-2010    Appendix 3B  
 
23-Jul-2010    Appendix 3B  
 
21-Jul-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
21-Jul-2010    SpringTree becomes a substantial shareholder  
 
21-Jul-2010    Appendix 3B  
 
21-Jul-2010    Appendix 3B  
 
24-Jun-2010    Appendix 3B  
 
21-Jun-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
21-Jun-2010    Appendix 3B (options)  
 
21-Jun-2010    Appendix 3B (shares)  
 
27-May-2010    Appendix 3B  
 
25-May-2010    Results of Meeting  
 
25-May-2010    CEO Presentation to AGM  
 
21-May-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
21-May-2010    Appendix 3B  
 
21-May-2010    Appendix 3B  
 
6-May-2010    Neuren Starts Phase II Trial of NNZ2566  
 
27-Apr-2010    Notice of Annual General Meeting/Proxy Form  
 
23-Apr-2010    Appendix 3B (convertible note)  
 
21-Apr-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
21-Apr-2010    Appendix 3B (options)  
 
21-Apr-2010    Appendix 3B (shares)  
 
6-Apr-2010    Lapse of unquoted options  
 
30-Mar-2010    Annual Report to shareholders  
 
25-Mar-2010    Appendix 3B - ESOP  
 
24-Mar-2010    Appendix 3B (convertible note)  
 
22-Mar-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
22-Mar-2010    Appendix 3B  
 
22-Mar-2010    Appendix 3B  
 
19-Mar-2010    Grant funding for TFF oncology program  
 
3-Mar-2010    Trial of Second Neuren Drug Motiva to be Initiated  
 
26-Feb-2010    Preliminary Final Report  
 
22-Feb-2010    Appendix 3B (convertible note)  
 
18-Feb-2010    Notice under section 708A(5)(e) of the Corporations Act  
 
18-Feb-2010    Appendix 3B (options)  
 
18-Feb-2010    Appendix 3B (shares)  
 
12-Feb-2010    Ceasing to be a substantial holder  
 
12-Feb-2010    Change in substantial holding  
 
12-Feb-2010    Change in substantial holding  
 
12-Feb-2010    Change in substantial holding  
 
11-Feb-2010    Cato strategic partnership and appoints US CMO  
 
20-Jan-2010    Appendix 3B  
 
13-Jan-2010    Change in substantial holding  
 
24-Dec-2009    Change of Director`s Interest Notice  
 
23-Dec-2009    Notice under section 708A(5)(e) of the Corporations Act  
 
23-Dec-2009    Appendix 3B (options)  
 
23-Dec-2009    Appendix 3B (shares)  
 
23-Dec-2009    Neuren Completes Shareholder Approved Funding  
 
22-Dec-2009    Results of Special Shareholders Meeting  
 
15-Dec-2009    Initial Director`s Interest Notice  
 
4-Dec-2009    Notice under section 708A(5)(e) of the Corporations Act  
 
4-Dec-2009    Appendix 3B  
 
4-Dec-2009    Notice of Special Shareholders Meeting  
 
25-Nov-2009    Dr John Holaday joins Neuren Board  
 
18-Nov-2009    Appendix 3B (options)  
 
18-Nov-2009    Notice under section 708A(5)(e) of the Corporations Act  
 
18-Nov-2009    Appendix 3B (notes)  
 
18-Nov-2009    Appendix 3B (shares)  
 
18-Nov-2009    Neuren Arranges up to AU$7.8m in New Funding  
 
18-Nov-2009    Reinstatement to Official Quotation  
 
16-Nov-2009    Suspension from Official Quotation  
 
12-Nov-2009    Trading Halt  
 
25-Sep-2009    Notice under section 708A(5)(e) of the Corporations Act  
 
25-Sep-2009    Appendix 3B  
 
22-Sep-2009    Reponse to Price Query  
 
31-Aug-2009    Half Year Report and Accounts  
 
14-Aug-2009    Appendix 3B  
 
14-Aug-2009    Neuren raises NZ$1 million through SPP  
 
22-Jul-2009    Neuren SPP section 708A notice  
 
21-Jul-2009    SPP NZ Certification  
 
20-Jul-2009    Neuren NNZ-2566 Development Overview  
 
20-Jul-2009    Neuren Share Purchase Plan  
 
20-Jul-2009    Neuren Chairmans SPP Letter  
 
15-Jul-2009    SPP terms update  
 
10-Jul-2009    Neuren Share Purchase Plan  
 
2-Jul-2009    Ceasing to be a substantial holder  
 
1-Jul-2009    Neuren obtains further US$14m US Army funding  
 
28-May-2009    Results of Meeting  
 
28-May-2009    Presentation to AGM  
 
28-May-2009    Chairman`s Address to Shareholders  
 
28-Apr-2009    Notice of Annual General Meeting/Proxy Form  
 
22-Apr-2009    Neuren Progresses Cancer Program  
 
21-Apr-2009    Trading Halt  
 
17-Apr-2009    Response to ASX Price Query  
 
16-Apr-2009    Trading Halt  
 
1-Apr-2009    Lapse of unquoted options  
 
31-Mar-2009    Annual Report to shareholders  
 
30-Mar-2009    Final Director`s Interest Notice  
 
27-Feb-2009    Preliminary Final Report  
 
21-Jan-2009    Neuren Strategy Update  
 
20-Jan-2009    Respone to ASX price query  
 
19-Jan-2009    Trading Halt  
 
14-Jan-2009    Change of Director`s Interest Notice  
 
24-Dec-2008    Neuren Announces Glypromate Trial Preliminary Results  
 
10-Nov-2008    Phase 3 trial data collection completed  
 
30-Sep-2008    Appendix 3B  
 
30-Sep-2008    Change of Director`s Interest Notice  
 
30-Sep-2008    Change of Director`s Interest Notice  
 
30-Sep-2008    Neuren raises $2m through underwritten SPP  
 
30-Sep-2008    Appendix 3B  
 
4-Sep-2008    US Army to provide additional NNZ2566 trial funding  
 
29-Aug-2008    Half Yearly Report and Accounts  
 
28-Aug-2008    Results of Special Shareholders` Meeting  
 
27-Aug-2008    Neuren extends SPP closing date  
 
27-Aug-2008    Neuren signs cancer license and collaboration agreement  
 
21-Aug-2008    NZ Securities Act certification for SPP  
 
15-Aug-2008    Share Purchase Plan letter to eligible shareholders  
 
15-Aug-2008    Notice under section 708A(5)(e) of the Corporations Act  
 
12-Aug-2008    Change in substantial holding  
 
12-Aug-2008    Notice of Special Meeting  
 
6-Aug-2008    Neuren Share Purchase Plan  
 
6-Aug-2008    Appendix 3B  
 
6-Aug-2008    Neuren raises a minimum of $3 million  
 
6-Aug-2008    Reinstatement to Official Quotation  
 
4-Aug-2008    Voluntary Suspension extended  
 
31-Jul-2008    Suspension from Official Quotation  
 
29-Jul-2008    Trading Halt  
 
21-Jul-2008    Glypromate and NNZ 2566 in Top 10 Neuroscience Projects  
 
16-Jul-2008    NEU Completes Glypromate Phase 3 Recruitment  
 
30-Jun-2008    Neuren to get early results from Glypromate trial  
 
29-May-2008    Results of Meeting  
 
29-May-2008    CEO presentation to AGM  
 
26-May-2008    Response to ASX Query re: Appendix 4C  
 
15-May-2008    Positive interim safety analysis for Glypromate  
 
29-Apr-2008    Quarterly Update to Shareholders April 2008  
 
29-Apr-2008    Notice of Annual General Meeting/Proxy Form  
 
31-Mar-2008    Annual Report to shareholders  
 
18-Mar-2008    Co-CEOs remuneration packages  
 
29-Feb-2008    Appendix 4E Preliminary Final Report  
 
26-Feb-2008    Appendix 3B  
 
18-Feb-2008    Form 604  
 
13-Feb-2008    Becoming a substantial holder  
 
11-Feb-2008    Change of Director`s Interest Notice  
 
11-Feb-2008    Change of Director`s Interest Notice  
 
11-Feb-2008    Rights issue raises $7.1m and notes convert  
 
11-Feb-2008    Substantial shareholder notice  
 
7-Feb-2008    Change in substantial holding  
 
7-Feb-2008    Appendix 3B - shares issued on conversion of notes  
 
7-Feb-2008    Appendix 3B - allotment of rights issue underwriter shares  
 
5-Feb-2008    Notice under section 708A(5)(e)  
 
1-Feb-2008    Appendix 3B - allotment of rights issue shares  
 
31-Jan-2008    Neuren Appendix 4C December 2007  
 
31-Jan-2008    Results of Rights Issue  
 
21-Jan-2008    US Department of Defense Approves NNZ2566 Funding  
 
17-Jan-2008    Glypromate trial recruits 100th patient  
 
9-Jan-2008    Neuren Confirms Despatch of Rights Issue Offer Documents  
 
9-Jan-2008    Section 708AA Notice